Hanall Biopharma Cash Flow Conversion Efficiency
Hanall Biopharma cash flow conversion efficiency. Based on the latest financial reports, Hanall Biopharma (009420) has a cash flow conversion efficiency ratio of 0.047x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩7.34 Billion ≈ $4.98 Million USD) by net assets (₩157.65 Billion ≈ $106.84 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Hanall Biopharma (2011–2024)
Cash flow conversion efficiency of Hanall Biopharma from 2011 to 2024. This chart illustrates how Hanall Biopharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Hanall Biopharma (009420) stock price for real-time trading data and today's change.
Hanall Biopharma Cash Flow Conversion Ratio Explained
Hanall Biopharma cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Hanall Biopharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hanall Biopharma ranked by their cash flow conversion efficiency. Also see Hanall Biopharma (009420) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Kingdom SCI Tech Co Ltd
SHG:600446
|
0.005x |
|
UMH Properties Inc
NYSE:UMH
|
0.025x |
|
ACV Auctions Inc.
NASDAQ:ACVA
|
0.024x |
|
Shanxi Zhangze Electric Power Co Ltd
SHE:000767
|
0.120x |
|
Fufeng Group Limited
F:FFO1
|
0.034x |
|
Del Monte Corporation
NYSE:DMC
|
0.027x |
|
Rianlon Corp
SHE:300596
|
0.066x |
|
REDOX Ltd
AU:RDX
|
0.066x |
Annual Cash Flow Conversion Efficiency for Hanall Biopharma (2011–2024)
The table below shows the annual cash flow conversion efficiency of Hanall Biopharma from 2011 to 2024. Review Hanall Biopharma (009420) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩168.35 Billion ≈ $114.09 Million |
₩9.36 Billion ≈ $6.34 Million |
0.056x | -65.07% |
| 2023-12-31 | ₩186.22 Billion ≈ $126.20 Million |
₩29.64 Billion ≈ $20.09 Million |
0.159x | +6.27% |
| 2022-12-31 | ₩168.26 Billion ≈ $114.03 Million |
₩25.20 Billion ≈ $17.08 Million |
0.150x | +2816.00% |
| 2021-12-31 | ₩163.49 Billion ≈ $110.80 Million |
₩839.87 Million ≈ $569.17K |
0.005x | +0.21% |
| 2020-12-31 | ₩181.27 Billion ≈ $122.85 Million |
₩929.29 Million ≈ $629.77K |
0.005x | -96.49% |
| 2019-12-31 | ₩140.42 Billion ≈ $95.16 Million |
₩20.49 Billion ≈ $13.89 Million |
0.146x | +669.79% |
| 2018-12-31 | ₩116.92 Billion ≈ $79.23 Million |
₩-2.99 Billion ≈ $-2.03 Million |
-0.026x | -106.76% |
| 2017-12-31 | ₩111.20 Billion ≈ $75.36 Million |
₩42.14 Billion ≈ $28.56 Million |
0.379x | +901.08% |
| 2016-12-31 | ₩104.36 Billion ≈ $70.72 Million |
₩3.95 Billion ≈ $2.68 Million |
0.038x | +893.87% |
| 2015-12-31 | ₩95.22 Billion ≈ $64.53 Million |
₩-454.02 Million ≈ $-307.69K |
-0.005x | +93.79% |
| 2014-12-31 | ₩45.81 Billion ≈ $31.04 Million |
₩-3.52 Billion ≈ $-2.38 Million |
-0.077x | +41.14% |
| 2013-12-31 | ₩59.63 Billion ≈ $40.41 Million |
₩-7.78 Billion ≈ $-5.27 Million |
-0.130x | -567.19% |
| 2012-12-31 | ₩78.67 Billion ≈ $53.31 Million |
₩2.20 Billion ≈ $1.49 Million |
0.028x | -80.90% |
| 2011-12-31 | ₩50.70 Billion ≈ $34.36 Million |
₩7.41 Billion ≈ $5.02 Million |
0.146x | -- |
About Hanall Biopharma
Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, … Read more